SG Americas Securities LLC lifted its stake in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 374.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,443 shares of the biotechnology company’s stock after purchasing an additional 37,440 shares during the quarter. SG Americas Securities LLC owned about 0.11% of Albany Molecular Research worth $1,030,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in AMRI. Chicago Capital Management LLC purchased a new stake in shares of Albany Molecular Research during the second quarter worth approximately $21,417,000. Longfellow Investment Management Co. LLC purchased a new stake in shares of Albany Molecular Research during the second quarter worth approximately $5,967,000. Royce & Associates LP raised its stake in shares of Albany Molecular Research by 17.6% during the first quarter. Royce & Associates LP now owns 1,518,276 shares of the biotechnology company’s stock worth $21,301,000 after purchasing an additional 227,365 shares during the last quarter. Kassirer Asset Management Corp purchased a new stake in shares of Albany Molecular Research during the second quarter worth approximately $3,936,000. Finally, Morgan Stanley raised its stake in shares of Albany Molecular Research by 18.7% during the first quarter. Morgan Stanley now owns 731,638 shares of the biotechnology company’s stock worth $10,264,000 after purchasing an additional 115,040 shares during the last quarter. Institutional investors and hedge funds own 72.10% of the company’s stock.

Several equities research analysts have recently commented on AMRI shares. Morgan Stanley cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target for the company. in a research note on Thursday, May 11th. They noted that the move was a valuation call. William Blair restated an “outperform” rating on shares of Albany Molecular Research in a research note on Tuesday, May 23rd. First Analysis cut Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. BidaskClub cut Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Finally, J P Morgan Chase & Co cut Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. Five research analysts have rated the stock with a hold rating, The company presently has an average rating of “Hold” and a consensus price target of $18.00.

ILLEGAL ACTIVITY NOTICE: “SG Americas Securities LLC Has $1.03 Million Stake in Albany Molecular Research, Inc. (AMRI)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/04/sg-americas-securities-llc-has-1-03-million-stake-in-albany-molecular-research-inc-amri.html.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) opened at 21.74 on Monday. The stock’s market cap is $905.82 million. Albany Molecular Research, Inc. has a 1-year low of $13.01 and a 1-year high of $22.17. The stock’s 50 day moving average price is $21.72 and its 200 day moving average price is $18.41.

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Stock Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related stocks with our FREE daily email newsletter.